Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients

被引:11
|
作者
Arafat, Waleed [1 ,2 ,3 ]
Darwish, Azza [1 ]
Naoum, George E. [2 ]
Sameh, Wael [4 ]
El Husseiny, Gamal [1 ]
Abd-El-Gawad, Fathy [1 ]
Samir, Mostafa [2 ]
机构
[1] Univ Alexandria, Fac Med, Oncol Dept, Alexandria, Egypt
[2] Alexandria Comprehens Canc Ctr, Alexandria, Egypt
[3] Univ Alabama Birmingham, 1720 2nd Ave S, Birmingham, AL 35233 USA
[4] Univ Alexandria, Urol Dept, Fac Med, Alexandria, Egypt
来源
ECANCERMEDICALSCIENCE | 2016年 / 10卷
关键词
bladder cancer; lymph nodes; radiotherapy; trimodality protocol;
D O I
10.3332/ecancer.2016.682
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Our aim is to compare the toxicity, pelvic nodal relapse, and overall survival of whole bladder irradiation only to the standard technique of whole pelvis irradiation followed by bladder boost in patients with muscle-invasive bladder carcinoma undergoing bladder preservation protocol. Material and method: A total of 60 patients with transitional cell carcinoma, stage T2-3, N0, M0 bladder cancer were subjected to maximal transurethral resection bladder tumour (TURB). Then, the patients were randomised into two groups: group I (30 patients) to receive whole pelvis radiotherapy 44 Gy followed by 20 Gy bladder boost. While group II (30 patients) were randomised to receive whole bladder radiotherapy alone for a total dose of 64 Gy. In both groups, concomitant cisplatin and paclitaxel were given weekly throughout the whole course of radiotherapy where conventional 2 Gy/fraction were used. Additionally, four cycles of adjuvant cisplatin and paclitaxel were given after the end of the chemoradiotherapy induction course. Results: The first assessment after the induction chemoradiotherapy showed that complete response was achieved in 73.3% of patients in group I and 76.7% of the patients in group II. After a median follow-up of 2 years, regional relapse occurred in 7.1% of patients in group I and 10.3% in group II. (p = 1). Distant metastases were detected in 17.9% of patient in group I and 13.8% in group II (p = 0.73). The 2-year disease-free survival was 60% in group I and 63.3% in group II (p = 0.79). The whole 2-year overall survival was 75% in group I and 79.3% in group II (p = 0.689). Radiation gastrointestinal (GI) acute toxicity was higher in group I than in group II (p = 0.001), while late GI radiation toxicity was comparable in both groups. Conclusion: Treating the bladder only, without elective pelvic nodal irradiation, did not compromise pelvic control rate, but significantly decreased the acute radiation toxicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] COMPARISON BETWEEN STANDARD AND REDUCED VOLUME RADIOTHERAPY IN BLADDER PRESERVATION TRIMODALITY PROTOCOL FOR MUSCLE INVASIVE BLADDER CANCER PATIENT
    Arafat, W.
    Darwish, A.
    El Hussiny, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 265 - 265
  • [2] Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
    Chen, Ronald C.
    Shipley, William U.
    Efstathiou, Jason A.
    Zietman, Anthony L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (08): : 952 - 960
  • [3] Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Johnson, Skyler B.
    Yu, James B.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (09)
  • [4] Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Skyler B. Johnson
    James B. Yu
    Current Oncology Reports, 2018, 20
  • [5] Bladder preservation in muscle-invasive bladder cancer
    Stackl, W
    Baierlein, M
    Albrecht, W
    BRITISH JOURNAL OF UROLOGY, 1998, 82 (03): : 357 - 360
  • [6] Stereotactic Ablative Radiotherapy Boost to Bladder Tumor for Bladder Preservation in Patients with Muscle-Invasive Bladder Cancer
    Qin, S. B.
    Gao, X. S.
    Yu, W.
    Zhang, C. J.
    Hao, H.
    Yao, L.
    Bai, Y.
    Li, H. Z.
    He, Z. S.
    Wang, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S111 - S111
  • [7] A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer
    Portner, R.
    Bajaj, A.
    Elumalai, T.
    Huddart, R.
    Murthy, V.
    Nightingale, H.
    Patel, K.
    Sargos, P.
    Song, Y.
    Hoskin, P.
    Choudhury, A.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 31 : 1 - 7
  • [8] Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer
    Nguyen, Eric K.
    Yu, Hang
    Pond, Gregory
    Shayegan, Bobby
    Pinthus, Jehonathan H.
    Kapoor, Anil
    Mukherjee, Som D.
    Neville, Alan
    Lalani, Aly-Khan A.
    Hotte, Sebastien J.
    Corbett, Thomas B.
    Dayes, Ian S.
    Lukka, Himanshu R.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (04): : 122 - 129
  • [9] OUTCOMES OF BLADDER PRESERVATION THERAPY ON SURVIVAL IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER
    Ozaydin, Sukru
    Atas, Erman
    Karadurmus, Nuri
    Emirzeoglu, Levent
    Arpaci, Fikret
    ARCHIVOS ESPANOLES DE UROLOGIA, 2020, 73 (01): : 41 - 46
  • [10] Hypofractionated chemoradiotherapy for bladder preservation in muscle-invasive bladder cancer
    Krishnan, Anuradha
    Kashid, Sheetal
    Pansande, Namrata
    Maitre, Priyamvada
    Singh, Pallavi
    Joshi, Amit
    Phuralipatram, Reena
    Prakash, Gagan
    Pal, Mahendra
    Arora, Amandeep
    Murthy, Vedang
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2499 - S2502